A potential earnings short-squeeze play in the biotechnology and drugs complex is Regeneron Pharmaceuticals (REGN), which is set to release numbers on Wednesday before the market open. This fully integrated biopharmaceutical company discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. Wall Street analysts, on average, expect Regeneron to report revenue of $349.43 million on earnings of 96 cents per share.
Just recently, Bank of America/Merrill Lynch said it expects Regeneron's Eylea sales growth to increase. The firm issued a buy rating on the stock and a $190 price target. Lazard Capital also recently said that companies most likely to beat third quarter top-line consensus expectations are Questcor (QCOR), Regeneron, Alexion (ALXN) and Gilead (GILD).The current short interest as a percentage of the float for Regeneron Pharmaceuticals sits at 6.7%. That means that out of the 89.25 million shares in the tradable float, 4.99 million shares are sold short by the bears. From a technical perspective, REGN is currently trading above both its 50-day and 200-day moving averages, which is bullish. This stock has been uptrending very strong for the last four months, with shares soaring from a low of $107.31 to its recent high of $166.39 a share. During that uptrend, shares of REGN have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed REGN within range of triggering a near-term breakout trade post-earnings. If you're bullish on REGN, then I would wait until after its report and look for long-biased trades if this stock can manage to break out above some near-term overhead resistance at $166.39 a share with high volume. Look for volume on that move that tracks in at near or above its three-month average volume of 719,498 shares. If REGN triggers that breakout, then this stock will enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets are $175 to north of $180 a share. I would avoid REGN or look for short-biased trades if after earnings it fails to trigger that breakout and then drops below its 50-day moving average of $148.77 a share with high volume. If we get that action, then REGN will setup to re-test or possibly take out its next major support levels at $142.13 to $141.84 a share. Regeneron shows up on a list of 10 Companies That Prove Stock Picking Is Still Alive.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV